1. Home
  2. SNTG vs BIAF Comparison

SNTG vs BIAF Comparison

Compare SNTG & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sentage Holdings Inc.

SNTG

Sentage Holdings Inc.

HOLD

Current Price

$1.74

Market Cap

5.6M

Sector

Finance

ML Signal

HOLD

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

HOLD

Current Price

$0.40

Market Cap

4.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNTG
BIAF
Founded
2009
2014
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
4.5M
IPO Year
2020
2022

Fundamental Metrics

Financial Performance
Metric
SNTG
BIAF
Price
$1.74
$0.40
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
131.8K
3.1M
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,900,000.00
Revenue This Year
N/A
$20.95
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.49
52 Week Low
$1.58
$0.23
52 Week High
$12.70
$13.50

Technical Indicators

Market Signals
Indicator
SNTG
BIAF
Relative Strength Index (RSI) 39.13 30.94
Support Level $1.64 N/A
Resistance Level $2.10 $0.87
Average True Range (ATR) 0.13 0.05
MACD 0.00 0.01
Stochastic Oscillator 22.81 32.34

Price Performance

Historical Comparison
SNTG
BIAF

About SNTG Sentage Holdings Inc.

Sentage Holdings Inc is a financial service provider. The company offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Share on Social Networks: